therapy 2020  (Bio-Techne corporation)

Journal: NPJ precision oncology

Article Title: ALDH1A1 promotes PARP inhibitor resistance by enhancing retinoic acid receptor-mediated DNA polymerase θ expression.

doi: 10.1038/s41698-023-00411-x

Figure Lengend Snippet: Fig. 4 POLQ/Polθ expression is regulated by RAR signaling. a, b PEO1 and OVCAR3 cells were treated with RAR agonist CH55 or RAR antagonist AGN 193109 for 48 h, qRT-PCR and immunoblotting were conducted to determine the mRNA (a) and protein (b) levels of POLQ/ Polθ, respectively. The mRNA level of RARB was also determined to validate the effect of RAR agonist and antagonist on the RAR signaling. c, d PEO1 and OVCAR3 cells were transfected with two RARA siRNA for 48 h, qRT-PCR and immunoblotting were conducted to determine the mRNA (c) and protein (d) levels of RARA/RARα and POLQ/Polθ, respectively. Measurements were taken from distinct samples. N = 3, bar: s.d., **P < 0.01. The relative amounts of analyzed proteins were listed under the corresponding band. The arrow indicates the specific RARα band.

Article Snippet: All-trans-Retinoic Acid (ATRA) was purchased from Sigma Aldrich (Cat. No. R2625), RAR agonist CH55 (Cat. No. 2020) and RAR antagonist AGN 193109 (Cat. No. 5758) were purchased from Tocris Biosciences.

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Transfection